GOTHENBURG, Sweden, May 3 /PRNewswire/ -- Cellectricon, a leading provider of microfluidic & cell-based tools to improve and accelerate drug discovery, today announced collaboration with AstraZeneca, under which the companies will study the possibility of developing a new cell-based microfluidic screening platform. The collaboration aims to advance the performance of cell-based ion channel assays in screening applications.
"We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for drug discovery," says Dr. Mattias Karlsson, VP Research & Development at Cellectricon. "The fantastic market acceptance of Dynaflow, our first generation of microfluidic-based tools supports the unique possibilities the micro-scale format offers such as superior performance characteristics and robustness."
"We believe the Nanoflow system has the potential to expedite our efforts in ion channel drug discovery and we look forward to working in collaboration with Cellectricon," says Dr. Christer Nordstedt, VP Discovery Research Area CNS & Pain Control.
Cellectricon invents and develops new types of functional cell-based screening devices for applications in drug discovery and basic research. The company utilizes state-of-the-art interfaces to biological systems by employing novel microfabrication technologies and smart engineering solutions. This enables completely new types of assays and devices with superior performance characteristics and robustness. Cellectricon's products are designed to enable substantial increases in productivity at the highest data quality. The company currently offers two products for the life science market:
Dynaflow(TM) - Screening and lead optimization for drugs acting on ion channel receptors and safety pharmacology testing.
Cellaxess(TM) - Screening and transfection tool for cell-based assays in the fields of intracellular targets and RNA interference.
CONTACT: Contact Details: Susanne Fagerlund, Communications Manager,Phone: +46(0)31-760-35-15, E-mail: email@example.com